



PRINCIPAL


Principal Pharmaceuticals & Chemicals Ltd.

513, Palm Spring, Link Road, Malad West, Mumbai - 400 064

AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2012

Rs. In lacs except EPS

Sr. No.		3 Months ended 31st March, 2012 Audited	3 Months ended 31st Dec., 2011 Un-Audited	3 Months ended 31st March, 2011 Un-Audited	Year ended 31st March, 2012 Audited	Year ended 31st March, 2011 Audited
1	Net Sales/Income from Operations	4.97	5.55	4.50	19.52	18.00
2	Other Income	0.13	-	0.03	0.21	0.42
	Total Income	5.10	5.55	4.53	19.73	18.42
3	Total Expenditure					
a.	(Increase)/decrease in stock trade	-	-	-	-	-
b.	Consumption of raw materials / Purchases	-	-	-	-	-
c.	Staff Cost	0.38	0.37	0.37	1.50	1.50
d.	Power & Fuel & Oil	-	-	-	-	-
e.	Job processing charges	-	-	-	-	-
f.	Internet Business Development Cost	-	-	-	-	-
g.	Other expenditure	3.77	1.00	2.78	10.08	5.34
4	Interest	-	-	-	-	-
5	Depreciation & Amortisation	1.56	(10.02)	9.34	10.23	37.04
6	Profit/(Loss) before tax (1+2-3-4-5)	(0.61)	14.20	(7.96)	(2.08)	(25.46)
	Less :					
7	Provision for taxation	-	-	-	-	-
	- Current Year Tax	-	-	-	-	-
	- Deferred Tax	-	-	-	-	-
8	Net Profit /(Loss) (6-7)	(0.61)	14.20	(7.96)	(2.08)	(25.46)
	Extraordinary Items					
9	Less : Relisting Fee	-	-	-	(4.80)	-
10	Balance carried to the balance sheet	(0.61)	14.20	(7.96)	(6.88)	(25.46)
11	Paid-up equity share capital (Face value Rs. 10 each upto 30th March 2012. Post Reduction Face Value is reduced to Rs. 4/- each wef 31st March, 2012)	434.96	599.97	599.97	434.96	599.97
12	Reserve excluding revaluation reserves (Net of debit balance of Profit & Loss Account)				(336.94)	(690.06)
13	Basic & diluted EPS for the period, for the year to date & for the previous year (prior to extra ordinary item) (not to be annualised)	(0.01)	0.24	(0.13)	(0.03)	(0.42)
14	Basic & diluted EPS for the period, for the year to date & for the previous year (after extra ordinary item) (not to be annualised)	(0.01)	0.24	(0.13)	(0.11)	(0.42)
15	Aggregate of Non-Promoters' Shareholding					
	No. of shares (in lacs)	40.79	40.79	40.79	40.79	40.79
	Percentage of Shareholding	37.51%	67.99%	67.99%	37.51%	67.99%
16	Promoters and Promoter Group Shareholding					
	a. Pledged /Encumbered					
	- No. of Shares (in lacs)	-	-	-	-	-
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of Shares (as a % of total sharecapital of the company)	-	-	-	-	-
	b. Non - Encumbered					
	- No. of Shares (in lacs)	67.95	19.21	19.21	67.95	19.21
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
	- Percentage of Shares (as a % of total sharecapital of the company)	62.49%	32.01%	32.01%	62.49%	32.01%





PRINCIPAL

Statement of Assets & Liabilities as at 31st March, 2012

Rs. In Lakhs.

STANDALONE

Particulars	Audited As At 31st March, 2012	Audited As At 31st March, 2011
SHAREHOLDER'S FUND		
a) Capital	434.96	599.97
b) Reserve & Surplus	(336.94)	(690.06)
NON CURRENT LIABILITIES		
a) Long Term Borrowings	-	-
b) Deferred Tax Liabilities (Net)	-	-
c) Other Long Term Liabilities	27.33	222.31
d) Long Term Provisions	-	-
CURRENT LIABILITIES		
a) Short Term Borrowings	-	-
b) Trade Payables	-	-
c) Other Current Liabilities	7.67	6.07
d) Short Provisions	-	-
TOTAL EQUITY & LIABILITIES	133.02	138.29
NON CURRENT ASSETS		
a) Fixed Assets		
i) Tangible Assets	101.62	111.85
b) Non Current Investments	1.19	1.19
c) Deferred Tax Assets (Net)	-	-
d) Long Term Loans & Advances	20.90	20.05
e) Other Non Current Assets	-	-
Total Non Current Assets	123.71	133.09
CURRENT ASSETS		
a) Current Investments	-	-
b) Inventories	-	-
c) Trade Receivables	0.06	0.11
d) Cash & Bank balances	8.52	4.68
e) Short Term Loans & Advances	0.50	-
f) Other Current Assets	0.23	0.41
Total Current Assets	9.31	5.20
TOTAL	133.02	138.29

- 1 No separate segment results are provided as the total revenue of the Company is from i.e. Active Pharmaceuticals Intgrediaents (API) & Intermediates.
- 2 Excess depreciation and amotization charged in earlier years has been reversed during the 3rd and 4th quarter of 2011-12.
- 3 The Rehabilitation Scheme (RS) was approved by the Board for Industrial & Financial Reconstruction (BIFR) on 14th July, 2011 and the necessary rectification was approved on 26th March, 2012. The company has taken steps to implementing the RS and accordingly, has reduced its paid up capital by 60% and also issued fresh capital (partly as per the shceme) to the Promoters. Consequent to such reduction and fresh issue of capital, the company's NET WORTH turns positive and technically, the company is now eligible for getting discharged from Hon'ble BIFR. Necessary steps shall be taken as per the guidance of Monitoring Agency. The listing approval of the reduced capital and fresh capital is still awaited from the Bombay Stock Exhcnage and for the time being, the shaes of the company remains suspended from trading at BSE.
- 4 There were no complaints pending at the beginning of 4th Quarter . Complaints received during 4th Quarter - ONE; Complaints solved during 4th Quarter - ONE; Complaints pending at the end of 4th Quarter - NIL.
- 5 The above results for the quarter and year ended on 31s March, 2012 are audited. The above results have been reviewed by the Audit Committee and then approved by the Board of Directors in their respective meetings held on 31st May, 2012

Place : Mumbai

Dated : 31st May, 2012

By Order of the Board

Pradeep Malu
President & CEO

